A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The U.S. government named Ozempic among 15 drugs selected for ... The company also announced trial results for a higher-dose semaglutide (7.2 mg), showing a 20.7% reduction in body weight compared ...

The maximum semaglutide dose for weight loss is 2.4 milligrams (mg) per week ... The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in recent years.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.